Agent’s Review of Proposed Amendments and Supplements. During any period in which an Issuance Notice is pending, prior to amending or supplementing the Registration Statement (including any 462(b) Registration Statement) or the Prospectus (excluding any amendment or supplement through incorporation of any report filed under the Exchange Act), the Company shall furnish to the Agent for review, a reasonable amount of time prior to the proposed time of filing or use thereof, a copy of each such proposed amendment or supplement, and the Company shall not file or use any such proposed amendment or supplement without the Agent’s prior consent (not to be unreasonably withheld), and to file with the Commission within the applicable period specified in Rule 424(b) under the Securities Act any prospectus required to be filed pursuant to such Rule.
Appears in 2 contracts
Samples: Aeglea BioTherapeutics, Inc., Aeglea BioTherapeutics, Inc.
Agent’s Review of Proposed Amendments and Supplements. During any period in which an Issuance Notice is pending, prior Prior to amending or supplementing the Registration Statement (including any Rule 462(b) Registration Statement, but excluding any supplement relating to an offering of securities other than the Shares) or the Prospectus (excluding any amendment or supplement through incorporation by reference of any report filed under the Exchange Act), the Company shall furnish to the Agent for review, a reasonable amount of time prior to the proposed time of filing or use thereof, a copy of each such proposed amendment or supplement, and the Company shall not file or use any such proposed amendment or supplement without the Agent’s prior consent, which consent (shall not to be unreasonably withheld), and to file with the Commission within the applicable period specified in Rule 424(b) under the Securities Act any prospectus required to be filed pursuant to such Rule.
Appears in 1 contract
Samples: Athersys, Inc / New
Agent’s Review of Proposed Amendments and Supplements. During any period in which an Issuance Notice is pending, prior Prior to amending or supplementing the Registration Statement (including any Rule 462(b) Registration Statement) or the Prospectus (excluding including any amendment or supplement through incorporation of any report filed under the Exchange Act)Act in connection with this Agreement and the Shares) relating to the Shares, the Company shall furnish to the Agent for review, a reasonable amount of time prior to the proposed time of filing or use thereof, a copy of each such proposed amendment or supplement, and the Company shall not file or use any such proposed amendment or supplement without the Agent’s prior written consent, such consent (not to be unreasonably withheld)withheld or delayed, and to the Company shall file with the Commission within the applicable period specified in Rule 424(b) under the Securities Act any prospectus required to be filed pursuant to such Rule.
Appears in 1 contract
Agent’s Review of Proposed Amendments and Supplements. During any period in which an Issuance Notice is pending, prior Prior to amending or supplementing the Registration Statement (including any Rule 462(b) Registration Statement) or the Prospectus (excluding any amendment or supplement through incorporation of any report filed under the Exchange Act), the Company shall furnish to the Agent for review, a reasonable amount of time prior to the proposed time of filing or use thereof, a copy of each such proposed amendment or supplement, and and, if such proposed amendment or supplement relates to the matters contemplated by this Agreement, the Company shall not file or use any such proposed amendment or supplement without the Agent’s prior consent (not to be unreasonably withheld)consent, and to file with the Commission within the applicable period specified in Rule 424(b) under the Securities Act any prospectus required to be filed pursuant to such Rule.
Appears in 1 contract
Samples: HOOKIPA Pharma Inc.
Agent’s Review of Proposed Amendments and Supplements. During any period in which an Issuance Notice is pending, prior Prior to amending or supplementing the Registration Statement (including any registration statement filed under Rule 462(b) Registration Statementunder the Securities Act) or the Prospectus (excluding Prospectus, excluding, in each case, any amendment or supplement through incorporation of any report filed under the Exchange Act), the Company shall furnish to the Agent for review, a reasonable amount of time prior to the proposed time of filing or use thereof, a copy of each such proposed amendment or supplement, and the Company shall not file or use any such proposed amendment or supplement without the Agent’s prior consent (consent, which shall not to be unreasonably withheld), conditioned or delayed, and to file with the Commission within the applicable period specified in Rule 424(b) under the Securities Act any prospectus required to be filed pursuant to such Rule.
Appears in 1 contract
Agent’s Review of Proposed Amendments and Supplements. During any period in which an Issuance Notice is pending, prior Prior to amending or supplementing the Registration Statement (including Statement, any Rule 462(b) Registration Statement) Statement or the Prospectus (excluding any amendment or supplement through incorporation of any report filed under the Exchange Act), the Company shall furnish to the Agent for review, a reasonable amount of time prior to the proposed time of filing or use thereof, a copy of each such proposed amendment or supplement, insofar as such proposed amendment or supplement relates to the transactions contemplated hereby, and the Company shall not file or use any such proposed amendment or supplement without the Agent’s prior consent (not to be unreasonably withheld)consent, and to file with the Commission within the applicable period specified in Rule 424(b) under the Securities Act any prospectus required to be filed pursuant to such Rule.
Appears in 1 contract
Samples: Open Market Sale Agreement (Ayala Pharmaceuticals, Inc.)